Oragenics Advances Concussion Therapy Trial Amid Regulatory and Listing Challenges

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has provided updates on its Phase IIa feasibility trial of ONP-002 for mild traumatic brain injury (mTBI), its regulatory pathway in the United States, and its continued listing on NYSE American. The company has dosed nine participants across three active clinical sites in Australia: Alfred Health, Mackay, and Royal Adelaide Hospital. These sites are part of the ongoing trial assessing ONP-002, a potential first-in-class intranasal treatment for concussion and mTBI.

The company has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package submitted in July 2026. Oragenics is currently reviewing the FDA's feedback and remains focused on submitting an Investigational New Drug (IND) application by the end of 2026. This step is crucial for advancing ONP-002 into U.S. clinical trials, with Phase 2b studies planned to follow the Australian Phase IIa trial.

In parallel, Oragenics disclosed that it received a deficiency letter from NYSE American on Aug. 26, 2026, concerning stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance, and it intends to do so within the required timeframe. If the plan is accepted, Oragenics would be allowed to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of Feb. 25, 2028. This development underscores the financial challenges that clinical-stage companies often face while pursuing regulatory milestones.

The dual progress on the clinical and regulatory fronts, alongside the listing compliance efforts, reflects Oragenics' commitment to advancing its lead candidate while managing corporate governance obligations. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, according to the company's announcement.

For investors and stakeholders, the FDA's response and the upcoming IND submission are key milestones that could shape the company's trajectory. The outcome of the NYSE American compliance plan will also be closely watched, as it affects the company's ability to continue trading on the exchange. Oragenics is working to balance these priorities as it moves forward.

The full press release is available at https://nnw.fm/HZ5fb. For more details on Oragenics, visit the company's newsroom at https://nnw.fm/OGEN.